The approaches to the assessment of biosimilarity of biotechnological preparations: quality issues

Due to expiration of patents for most highly demanded biotechnological preparations there is a tendency for the increase in the number of applications for marketing authorisation of biosimilar preparations (biosimilars). In the Russian Federation, the process of bringing biosimilars to the market has just started. It should be expected that in the upcoming years the global tendency for brining biosimilars of previously authorized preparations will become real in Russia. In this regard there is a need for developing national requirements for drugs submitted for marketing authorization as biosimilars. In the present article the authors propose for consideration main approaches for selecting criteria for confirmation of biosimilarity in terms of their quality assessment and determining the amount of studies required to confirm the similarity and comparability of physical, chemical and biological properties of biosimilars in comparison with the originator.

оригинальный биотехнологический лекарственный препарат, биоаналоговый (биоподобный) лекарственный препарат, качество, исследования сопоставимости, производство, регистрация, original biotechnological products, biosimilar, quality, comparability studies, manufacture, marketing authorization

1. Summary of product characteristics. Inflectra. [cited 2014 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002778/WC500151489.pdf.

2. Summary of product characteristics. Remsima. [cited 2014 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002778/WC500151489.pdf.

3. Summary of product characteristics. Abasaglar. [cited 2014 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002835/WC500175381.pdf .

4. Advisory committee briefing materials: available for public release. FDA Oncologic Drugs Advisory Committee Meeting ZARXIO® (filgrastim). January 7, 2015. [cited 2014 Jan 23]. Available from: http://www.fda.gov/.

5. Guideline on similar biological medicinal products. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.

6. Guidance for Industry Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (draft guidance). [cited 2014 Jan 23]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf.

7. Guideline on similar biological medicinal products. [cited 2014 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf.

8. Guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: Non-clinical and clinical issues. [cited 2014 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.

9. Guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: quality issues. [cited 2014 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf.

10. Guidelines on evaluation of similar Biotherapeutic products (sbps). [cited 2014 Jan 23]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB _22APRIL2010.pdf?ua=1.

11. Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: quality issues (revision 1)/ [cited 2014 Jan 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf.

12. On Amendments to the Federal Law «On Circulation of Medicines». Federal Law № 429 of December 22, 2014 (in Russian).

13. Mironov AN, ed. Guideline on expertise of medicines. V. 4. Moscow: Poligraf Plus; 2014 (in Russian).

14. Guidance for Industry Q8(R2) Pharmaceutical Development. [cited 2014 Jan 23]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm073507.pdf.

15. Vaganova OA, Efremova TA, Mironov AN, et al. Directions for improving of medicines of monoclonal antibodies. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2014; 1: 32–39 (in Russian).

16. Soldatov AA, Avdeeva ZhI, Alpatova NA, et al. The aspects of biosimilar marketing approval process. Biopreparaty 2014; 4(52): 24–36 (in Russian).